Table 3. Clinicopathological features, tumour markers, and patient survival (multivariate analysis).
| Variable | 5-Year DFS HR (95% CI) | P-value | 5-Year OS HR (95% CI) | P-value |
|---|---|---|---|---|
| Model A | ||||
| Histology (poor/moderate vs well) | 1.31 (0.67–2.55) | 0.4342 | 1.75 (0.8–3.81) | 0.1619 |
| TNM stage (III/IV vs I/II) | 8.52 (2.11–24.33) | 0.0026 | 8.17 (1.76–27.28) | 0.0074 |
| Vascular invasion (yes vs no) | 1.32 (0.69–2.54) | 0.4034 | 1.55 (0.77–3.11) | 0.2169 |
| Lymphatic invasion (yes vs no) | 2.53 (0.96–6.67) | 0.061 | 1.50 (0.69–3.83) | 0.4004 |
| Lymph node metastasis (yes vs no) | 0.56 (0.21–1.53) | 0.259 | 0.49 (0.15–1.5) | 0.2058 |
| Liver metastasis (yes vs no) | 2.02 (1.04–3.92) | 0.0373 | 1.68 (0.79–3.58) | 0.1791 |
| Peritoneal metastasis (yes vs no) | 0.99 (0.43–2.31) | 0.9897 | 1.23 (0.49–3.08) | 0.655 |
| TLR4 (high vs low) | — | — | 1.39 (0.67–2.89) | 0.381 |
| MyD88 (high vs low) | 2.01 (1.00–4.03) | 0.0494 | 2.31 (1.09–4.89) | 0.0279 |
| Model B | ||||
| Histology (poor/moderate vs well) | 1.53 (0.81–2.89) | 0.1873 | 2.11 (1.02–4.37) | 0.0435 |
| TNM stage (III/IV vs I/II) | 7.17 (1.86–25.68) | 0.0043 | 5.56 (1.87–21.68) | 0.0216 |
| Vascular invasion (yes vs no) | 1.33 (0.69–2.56) | 0.3887 | 1.35 (0.77–3.11) | 0.2224 |
| Lymphatic invasion (yes vs no) | 2.85 (1.07–7.61) | 0.0362 | 1.74 (0.67–4.5) | 0.2522 |
| Lymph node metastasis (yes vs no) | 0.67 (0.25–1.75) | 0.4071 | 0.67 (0.22–1.96) | 0.4602 |
| Liver metastasis (yes vs no) | 1.97 (1.01–3.86) | 0.047 | 1.83 (0.87–3.83) | 0.1093 |
| Peritoneal metastasis (yes vs no) | 0.89 (0.38–2.11) | 0.8065 | 1.21 (0.5–2.9) | 0.6739 |
| TLR4+MyD88 (⩾5+ vs <5+) | 1.87 (0.97–3.59) | 0.0625 | 2.11 (1.05–4.23) | 0.0352 |
Abbreviations: DFS=disease-free survival; HR=hazard ratio; CI=confidence interval; OS=overall survival; TNM=tumour, node, metastasis; TLR4=Toll-like receptor 4; MyD88=myeloid differentiation factor 88. Bold values indicate P<0.05.